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 The more recent strategies in medicinal chemistry involve the pharmacokinetic profiling of new molecules as soon as possible 
in the development pipeline with the clear aim to develop only drug-like compounds.1
 Such an early pharmacokinetic analysis requires the achievement of a maximum of useful and relevant molecular descriptors to 
allow a reliable prediction of the drug-likeness.
 Among the barriers determining the bioavailability of peptide-like molecules, the intestinal absorption plays a crucial role
particularly for hydrophilic peptidomimetics, which rarely can be absorbed by passive permeation.
 This problem might be overcome increasing the affinity for the intestinal transporters which are involved in the absorption of 
digested dietary proteins.
 For peptide-like molecules, the ability to predict which compounds can be actively absorbed by intestinal carriers is an 
information even more relevant than the common physicochemical descriptors used in the pharmacokinetic screening (e.g. 
logP, log D, PSA).
 Among the intestinal carriers,2 the apical proton-dependent oligopeptide transporters (POT) play a key role in the absorption of 
both digested dietary proteins and peptidomimetics; In humans, two members of POT are found, namely hPepT1 and hPepT2.
 The hPepT1 transporter is a 708 residues protein, whose transmembrane bundle is composed by 12 helices. It is mainly 
expressed in the small intestine, in the proximal tubules of the kidney as well as in pancreatic, liver and renal cells.
 The known SARs suggest that (a) the best size corresponds to that of di/tripeptides; (b) the charged termini and amide groups 
are not mandatory; (c) the binding is highly stereospecific preferring L-residues; (d) the hydrophobic side chains are mostly 
favored.
Aim of the work3 was to generate a full-length model for the human intestinal transporter hPepT1 and to analyse the 
substrate recognition at an atomic level with a view to develop a computational strategy able to predict the affinity of 
new molecules for the hPepT1 transporter.
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The congruity of the obtained complexes and the agreement between docking results and pharmacophore 
mapping afford an encouraging validation for the here described hPepT1 which can be successfully used 
to predict the affinity of new molecules. The fragmental strategy appears a fertile methodology to model 
any transmembrane protein and the combined approach docking search plus pharmacophore mapping 
allows to deeply explore the molecular recognition at an atomic level.
Homology model for hPepT1
The Figure shows the hPepT1 model, colored by segments, unveiling its typical 
folding with 12 transmembrane segments (TM1-12) and a large extracellular loop 
(EL5). The structural quality of the model is assessed by the significant percentage 
of residues which fall in the allowed regions of the Ramachandran’s plot (70.62%) 
with a marked preponderance of helix motifs.
The TM bundle assumes an elliptical truncated conic shape, which is due to fact 
that the TM segments are far from being parallel and some segments are staggered 
with an angle of 30° in respect to the adjacent heli ces. The TMs arrangement does 
not agree the numerical order, but it is possible to recognize an internal group of 
helices (i.e. TM1, TM4, TM5, TM7, TM10), which line the central pore and bear the 
key residues for the binding, and an external set of TM segments (TM2, TM3, TM6, 
TM8, TM11, TM12), which define the boundary of TM bundle. Notably, the helices 
facing the central pore are clearly more hydrophilic than the external TM segments. 
The extracellular loop EL5 (red segment) fully covers the extracellular side and 
consists of two large domains connected by two hinge loops. The hinges may 
confer flexibility to the domains, which could assume closed or open conformations 
modulating the accessibility of the binding cavity. Such a flexibility is confirmed by 
the used template (sucrose phosphatase) which can assume two different states. 
Such template is a metalloenzyme which selectively recognizes some sugars. This 
suggests that also EL5 may bind sugars and/or metal ions involved in modulatory 
effects on hPePT1, as reported by experimental studies.
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The ammonium head 
probably plays the most 
critical role since it 
realizes a reinforced H-
bond with Tyr588 as well 
as ion-pairs with Glu23
(TM1) and/or Glu26
(TM1). Notably, the 
contact between Tyr588 
and ammonium head 
characterizes the most 
affinitive ligands.
The carboxy terminus 
appears less involved 
in ligand recognition, 
since it stabilizes only 
H-bonds with the 
backbone of Ala295
(TM7), Leu296 (TM7), 
and Phe297 (TM7) 
without forming strong 
ionic interactions
The residues which interact with the side chains are heterogeneous, justifying the ability of hPepT1 to 
interact with structurally diverse substrates. It is possible to recognize a set of residues involved in the 
interaction with the N-terminal side chain (SC1) such as Asn22 (TM1), Glu23, and Phe293, while the C-
terminal side chain (SC2) contact Trp294, Ile331 (TM8), and Glu291 (TM7) and Thr327 (EL4).
The central peptide bond can stabilize H-bonds with backbone atoms of Phe293 and Trp294. Such 
interactions can be hindered by bulky side chains, and, thus, one can conclude that the contacts of the 
peptide groups could partially counterbalance the reduced interactions stabilized by small side chains.
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The Figure shows that hPepT1 realizes a vast pattern of relevant
contacts also with tripeptides involving all ligand’s functional groups:
hPepT1-MetMetMet complex
Despite the clear heterogeneity among the docking results, a deeper analysis of all 
putative complexes allows the identification of the residues most frequently involved in 
the ligand recognition, which can be sum up as represented in the figure.
Docking-based affinity prediction
pKi = 0.235 ∆distance – 7.912 10-3 Zapbind +1.534 Int_Tyr588 - 0.480 
n = 50; r2 = 0.85; s = 0.45; F = 89.92
Docking results suggest that the most 
affinitive compounds have a distance 
between charged termini about equal to 6 
Å. ∆distance defines the difference 
between the distance value of a given 
ligand and the optimal distance (6.02 Å) 
as evidenced by the most affinitive 
ligand. Such descriptor reflects the 
significant role of the contacts stabilized 
by the charged termini 
Zapbind accounts for the ionic 
interactions. Despite the known 
predilection of hPepT1 for hydrophobic 
ligands, the role of Zapbind score 
emphasizes the relevance of the polar 
interactions mostly realized by the 
ligand’s charged groups. 
Given the beneficial role of the 
interaction between Tyr588 and 
ammonium head, we introduced a 
binary descriptor (Int_Tyr588), which 
is equal to 1 for substrates which 
realize such a reinforced H-bond and 
0 otherwise. Such a descriptor 
markedly enhances the predictive 
power of the equation. 
The figure confirms the goodness of the affinity predictions and, 
when considering the classification in more affinitive (pKi > 0) 
from less affinitive ligands (pKi < 0) as defined by Cartesian 
axes, one can note that equation is able to successfully 
discriminate among the docked ligands and only one derivative 
is incorrectly predicted giving a false positive (as evidenced by 
red circle). The badly predicted compound is the tripeptide Gly-
His-Lys that, in fact, gave a good docking pose (as exemplified 
by H-bond with Tyr588). 
Pharmacophore mapping
Computational methods4
To confirm the docking results, enriching our knowledge about the hPepT1 
binding, HypoRefine was exploited to derive a SAR pharmacophore model for 
hPepT1 ligands. 
The selected model consists of one hydrophobic region (H), two hydrogen-
bond acceptors (A1–A2), one hydrogen-bond donor (D) and eight excluded 
volume sites (E1–E8) in a specific three-dimensional arrangement. 
The Figure shows the pharmacophoric regions mapped on docking pose of 
most affinitive derivative (Tyr-(OBzl)-Ala). 
• The ammonium head occupies the H-bond donor region (D) which 
overlaps Tyr588, Asp23 and Asp26 
• the carboxylate and the peptide bond map the H-bond acceptor regions
(A1-A2) corresponding to Phe293, Trp294, Leu296, and Phe297 
• the hydrophobic region (H) corresponds to C-terminal side chain, 
suggesting that an hydrophobic residues is really beneficial in such position. 
• the excluded volumes (E1-E8) are mostly located near to C-terminus, 
while the N-terminus appears less sterically constrained. 
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• The ammonium head realizes ion-pairs with Glu23 and Glu26 plus the 
critical H-bond with Tyr588, suggesting that the contacts of ammonium 
head are constant and independent of the substrate’s length. 
• The carboxylate forms H-bonds with the backbone atoms of Tyr588 and 
Gln587 (TM10) instead of Ala295, Leu296, and Phe297 as shown by 
dipeptides.
• The peptide bonds stabilize H-bonds with the backbone atoms of 
Phe293, Trp294, Leu296, and Phe297.
• The side chains realizes hydrophobic contacts with Cys25 (TM1), 
Phe293, Trp294, Leu296, Phe297 plus a set of aliphatic residues. 
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